TrialBreast (Edinburgh, Scotland)2020

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

Andreas Schneeweiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.